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Abstract
AIM
To study the effect of itopride on gastric accom-
modation, gastric emptying and drinking capacity in 
functional dyspepsia (FD). 
METHODS 
Randomized controlled trial was conducted to check 
the effect of itopride on gastric accommodation, gastric 
emptying, capacity of tolerating nutrient liquid and 
symptoms of FD. We recruited a total of 31 patients 
having FD on the basis of ROME III criteria. After rand-
omization, itopride was received by 15 patients while 
16 patients received placebo. Gastric accommodation 
was determined using Gastric Scintigraphy. 13C labeled 
octanoic breadth test was performed to assess gastric 
emptying. Capacity of tolerating nutrient liquid drink 
was checked using satiety drinking capacity test. The 
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Randomized Controlled Trial
intervention group comprised of 150 mg itopride. 
Patients in both arms were followed for 4 wk. 
RESULTS
Mean age of the recruited participant 33 years (SD 
= 7.6) and most of the recruited individuals, i.e. , 21 
(67.7%) were males. We found that there was no effect 
of itopride on gastric accommodation as measured at 
different in volumes in the itopride and control group 
with the empty stomach (P  = 0.14), at 20 min (P  = 
0.38), 30 min (P  = 0.30), 40 min (P  = 0.43), 50 min 
(P  = 0.50), 60 min (P  = 0.81), 90 min (P  = 0.25) and 
120 min (P  = 0.67). Gastric emptying done on a sub 
sample (n  = 11) showed no significant difference (P = 
0.58) between itopride and placebo group. There was 
no significant improvement in the capacity to tolerate 
liquid in the itopride group as compared to placebo (P  = 
0.51). Similarly there was no significant improvement of 
symptoms as assessed through a composite symptom 
score (P  = 0.74). The change in QT interval in itopride 
group was not significantly different from placebo (0.10). 
CONCLUSION
Our study found no effect of itopride on gastric accommo-
dation, gastric emptying and maximum tolerated volume 
in patients with FD. 
Key words: Itopride; Gastric emptying; Gastric accom-
modation; Functional dyspepsia; Dyspepsia
© The Author(s) 2017. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip: Through this study we wanted to find the 
effect of itopride on gastric accommodation, gastric 
emptying and drinking capacity in patients with 
functional dyspepsia (FD) in Pakistani population. 
The strength of our study was that we used objective 
measures, i.e. , gastric scintigraphy and 13C labeled 
octanoic acid breath test to measure gastric accom-
modation and gastric emptying. Diagnosis of FD was 
based on ROME III criteria and was done after using 
extensive investigations to rule out organic cause 
for the symptoms. We found no effect of itopride on 
gastric accommodation, gastric emptying and maximum 
tolerated volume in patients with FD in our study. 
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INTRODUCTION
Patients presenting with epigastric pain and burning, 
early satiation and postprandial fullness without any 
structural, organic or systematic pathology are labeled 
as having functional dyspepsia (FD)[1,2]. Globally pre­
valence of FD varies from 1.8% to 57% depending on 
the geographic location and diagnostic criteria used[3]. 
There is no published data on community based pre­
valence of FD from South Asia but experts consider it 
to be an important problem for our population[3,4]. FD 
reduces productivity and incurs a considerable cost on 
health system[5]. Only in 2009 the cost incurred to the 
health system by this morbidity was $18 billion[6]. 
Muti-factorial pathogenesis of FD makes it a difficult 
condition to intervene[7]. These patients have inability 
of the stomach to change its volume in response to 
food, decreased stomach compliance and inability of 
the stomach to empty[7]. Delayed gastric empting is 
associated with the symptoms of nausea, vomiting and 
postprandial fullness[8]. These symptoms result in lower 
productivity of the patients and a compromised quality 
of life[7,9]. Delayed gastric emptying is found in one third 
of the patients with FD[8,10]. These patients showed 
slower gastric emptying as compare to the normal 
individuals[11]. This is because of sub optimal gastric 
myoelectric activities[12,13].
Different drug therapies used for FD that include 
eradication of Helicobacter pylori (H. pylori), use of 
proton pump inhibitors (PPIs) and anti­depressants 
failed to demonstrate a convincing effect[5,14,15]. Guide­
lines recommend eradication of H. pylori but this 
treatment alone depends on the type of the FD being 
treated[15]. Evidence in favor of efficacy for using PPIs 
for all the patients with FD is not clear[16]. It’s argued 
that PPIs may only be effective in patients having co­
morbid reflux symptoms[16]. Though data suggest that 
anti-depressants like mirtazapine might be beneficial for 
some sub­groups of FD but still more studies are needed 
to recommend its usage for all patients with FD[17]. 
Symptoms of FD are improved by prokinetic agents[18]. 
Metoclopramide can cause extra pyramidal movement 
disorders[19]. Use of domperidone can result in rise in 
prolactin level leading to gynaecomastia[20]. Cisapride 
can result in prolonged QT interval and arrhythmias[21]. 
Itopride is a dopamine (D2) antagonist with peripheral 
action. It doesn’t cause severe elevation of prolactin 
and or pathological changes on electrocardiogram 
(ECG)[22]. A recent meta­analysis concluded that itopride 
improves the symptoms of early satiety and postprandial 
fullness[23]. Through this study we wanted to find the 
effect of itopride on gastric accommodation, gastric 
emptying and capacity of tolerating nutrient liquid drink 
in patients with FD in Pakistani population. 
MATERIALS AND METHODS
We conducted a randomized controlled trial to see the 
effect of itopride on gastric emptying. This study was 
conducted after approval from Aga Khan University 
Ethical Review Committee (Clinical trial registration 
number: NCT01226134). Subject for this study were 
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enrolled after written informed consent that was made 
on the basis of declaration of Helsinki. 
Study population 
Total of 31 patients were recruited for the purpose of 
this study from the gastroenterology clinics of Aga Khan 
University Hospital. Eligibility criteria used for recruiting 
these patients was; age equal to or greater than 18 
years, diagnosed as FD on the base of Rome III criteria, 
negative for H. pylori on gastric biopsy and Urea Breath 
Test, negative duodenal biopsy for giardiasis or celiac 
disease or any other established organic pathology, 
and normal upper abdominal ultrasound. We excluded; 
pregnant women, patients taking other medications 
that alter gastric motility like macrolide and anti­emetics 
and antibiotics. 
Randomization 
Before undergoing randomization patients were asse­
ssed for symptoms that included epigastric discom­
fort, heart burn, acid regurgitation, upper abdominal 
pain, belching, nausea, early satiety, and postprandial 
fullness. Blood samples of these patients were taken 
to check for serum hemoglobin level, white blood cell 
count, platelet count, serum alanine aminotransferese 
(SGPT) and prolactin level. Electrocardiogram of the 
patient was performed to find out the QT interval at 
the baseline. Single photon emission tomography 
and satiety drinking test was performed to measure 
gastric accommodation at baseline. After completing 
the baseline investigations, out of all patients that were 
recruited 15 were randomly allocated to the intervention 
group while 16 were randomly allocated to the placebo 
group. Patients in the intervention group received 150 
mg of itopride for 4 wk. Patients were instructed to take 
antacids as and when required. 
Outcome measures 
Gastric accommodation: Gastric accommodation was 
determined by estimating the change in gastric volumes 
using Gastric Scintigraphy and by the help of computer 
software which convert the gastric images into 3D 
images and calculate the estimated gastric volumes[24]. 
Gastric volumes were determined before giving itopride 
or placebo agent and after completion of intervention 
period. We injected 99mTc pertechnetate followed 
by the use of Analyze software for reconstruction of 
tomographic images. These images were acquired after 
an overnight fast among all the participants and then 
after giving 300 mL of nutrient drink at an interval of 
20, 30, 40, 50, 60, 90 and 120 min. Analyze PC 2.5 
software system was used to find out stomach volume 
measurements[24]. 
Gastric emptying: After an overnight fast, 13C labeled 
octanoic breadth test was performed to assess gastric 
emptying[25,26]. A test meal containing 13C was given to 
patient which is supposed to be completed in 10 min. 
Breath sample was taken before test meal (150 mL of 
water with a sandwich of scrambled egg containing 13C 
octanoic acid and 250 mL of orange juice) and at an 
interval of every 15 min for 4 h and then half­hourly for 
another two hours. During the measurement time the 
subject remained sedentary while reading or watching 
television. If necessary limited movements between the 
breaths collections were permitted. 
Satiety drinking capacity test: Subjects after an 
overnight fast were told to come at 8:30 AM in the 
morning. They were asked to grade their satiety from 0 
to 5 (5 being the maximum satiety). A drink containing 
6.5 g fat/100 mL, 1.1 g carbohydrate and 5 g of protein 
(nutridrink kcl 150/100 mL) which tasted of vanilla was 
taken by the participants at room temperature. Subjects 
drank at the rate of 15 mL/min. Symptoms were scored 
at every five minutes interval. Test was ceased once a 
score of 5 is achieved[27].
Symptoms of FD: Dyspeptic symptoms which included 
epigastric pain, epigastric discomfort, heart burn, acid 
regurgitation, upper abdominal pain, belching, nausea, 
early satiety and postprandial fullness were assessed 
at baseline and at 4 wk with validated 7­point global 
overall symptom scale[28].
Sample size calculation
Change in gastric volumes between baseline and post­
prandial (accommodation) was the primary endpoint for 
this study. To detect 16% difference in the Itopride and 
placebo with power of 80% and 5% level of significance 
a sample size of 15 subjects was needed in each group. 
This effect size of 16% [100 × (difference in group 
means divided by overall mean of the two groups)] 
corresponds to the difference in the two groups that 
was relevant clinically. The Analysis of coefficient of 
variance (ANCOVA) was done for this analysis.
Statistical analysis 
For the purpose of this study, mean and standard devia­
tion were reported for quantitative variables. Means and 
standard errors adjusted for covariates were reported 
using ANCOVA. The difference in the change in volume 
between itporide and the placebo group was compared 
using Man Whitney U test. 
RESULTS
A total of thirty­one individuals were recruited for the 
purpose of this study. Mean age of these individuals was 
33 years. Most of the recruited individuals, 21 (67.7%) 
were males. After randomization into Itopride and 
placebo groups, the groups were similar on variables 
like age, gender, serum haemoglobin, white blood cells, 
platelet count, serum creatinine, SGPT, prolactin level 
and QT interval on ECG (Table 1). There was no lost to 
follow up. 
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there was no significant improvement in the capacity 
to tolerate liquid in the itopride group as compared to 
placebo (P = 0.51) (Figure 3). 
Symptoms of FD 
There was no significant improvement of symptoms 
as assessed through a composite symptom score (P = 
0.74) in the intervention group as compared to placebo 
(Figure 4). Similarly we didn’t find any significant 
improvement in the individual symptoms that included 
epigastric pain (P = 0.83), epigastric discomfort (P = 
0.22), heart burn (P = 0.74), upper abdominal pain (P 
= 0.51), nausea (P = 0.08), early satiety (P = 0.34) 
and postprandial fullness (P = 0.25) (Table 3). 
The change in QT interval as a result of itopride 
group was not statistically different from placebo (0.10). 
Similarly itopride didn’t alter the serum prolactin level 
in the intervention group as compare to the placebo 
group. 
Gastric accommodation 
Gastric accommodation was checked using gastric 
scintigraphy by computing the change in gastric volume 
at empty stomach, 20, 30, 40, 50, 60, 90 and 120 
min. We found that there was no statistically significant 
difference in the itopride and placebo group on gastric 
accommodation as measured with the difference in 
volume in the itopride and control group with the 
empty stomach (P = 0.14), at 20 min (P = 0.38), 30 
min (P = 0.30), 40 min (P = 0.43), 50 min (P =0.50), 
60 min (P = 0.81), 90 min (P = 0.25) and 120 min (P 
= 0.67) (Figure 1). Mean volumes to measure gastric 
accommodation by scintigraphy using ANCOVA adjusted 
for age and gender were computed (Table 2). 
Gastric emptying 
Gastric emptying was done by doing breath tests 
on a sub sample (n = 11). There was no statistically 
significant difference (P = 0.58) between intervention 
and control group in gastric emptying (Figure 2). 
Capacity of tolerating liquid drink 
At the end of the intervention (Itopride or placebo) 
  Variable Itopride Placebo P  value 
  Age mean (SD) 34.2 (6.4) 31.9 (8.5) 0.40
  Gender n (%)
     Male      10 (66.7)      11 (68.8) 1.001
     Female        5 (33.3)        5 (31.3)
  Hb (g/dL) mean (SD) 13.6 (2.3) 14.1 (1.7) 0.50
  WBC (× 10 Eq/L) mean (SD)   8.1 (2.0)   7.7 (1.9) 0.52
  Platelet count (× 10 Eq/L) mean (SD) 257.3 (59.5) 250.5 (57.2) 0.75
  Creatinine (mg/mL) median (IQR)   0.9 (0.5)   0.8 (0.3) 0.05
  SGPT (IU/L) median (IQR)    20 (9.0)   25.5 (17.0) 0.09
  Prolactin level (mg/mL) (IQR)   7.3 (3.6)   5.7 (2.7) 0.29
  QT interval mean (SD) 394.1 (21.6) 399.2 (22.9) 0.53
Table 1  Distribution of age and gender by intervention arm 
n = 31
1Fischer Exact test. WBC: White blood cell; IQR: Interquartile range.
  Mean (± SE) Itopride Placebo 
  Change in volume (post-pre) using 
  scintigraphy
     Fasting -22.2 (± 15.4)     7.5 (± 14.9)
     20 min -201.7 (± 102.4) -31.5 (± 99.1)
     30 min  0.14 (± 22.8) -36.4 (± 22.1)
     40 min -27.6 (± 32.2) -37.4 (± 31.2)
     50 min -60.0 (± 31.2)   -3.0 (± 30.2)
     60 min   -3.1 (± 36.5)   15.0 (± 35.4) 
     90 min    3.8 (± 29.8) -31.8 (± 28.8)
     120 min  16.7 (± 28.9)  23.3 (± 28.0)
  Effect on gastric emptying on 13C 
  labeled octanoic acid breath test 
  (post-pre)
 0.4 (± 0.4)  0.2 (± 0.4) 
  Effect on drinking capacity (post-pre)     22.5 (± 18.1)     36.0 (17.5) 
  Change in Symptom score (post-pre)      -5.8 (1.0)     -4.7 (0.9) 
Table 2  Mean volumes to measure gastric accommodation by 
scintigraphy using ANCOVA adjusted for age and gender
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Figure 1  Schintigraphy.
Figure 2  Breadth test.
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that itopride improves symptoms related to FD but we 
found that it is not true for our set of patients. Itopride 
failed to show improvement in the overall symptom 
score as well as effect on individual symptoms including 
early satiety and postprandial fullness as opposed to 
the conclusion of a recent meta­analysis[23]. Through 
previous studies we know that to achieve a considerable 
improvement in the symptoms of one patient, we need 
to treat six patients of FD[32]. Itopride was efficacious in 
reducing the symptom score in Chinese patients having 
FD[33]. Small sample size might be the reason which 
resulted in our inability to detect an improvement in 
individual symptoms as a result of itopride usage as 
compared to placebo. Our sample included younger 
individuals and therefore could not study the effect of 
itopride in older patients with FD. Lack of variability in 
the age might have affected the results. 
Itopride is advocated for the treatment of FD as it 
is safer drug as compare to other prokinetic agents. In 
our study we found that itopride didn’t prolong the QT 
interval compared to placebo. Similarly itopride did not 
raise the prolactin level compared placebo. Therefore 
we can say that though itopride did not demonstrate 
any effect it is safer prokinetic. 
Inability of itopride to effect gastric accommodation 
and gastric emptying might be because of the genetic 
variability in the dopamine­D2 receptor subtype. TaqIA 
DISCUSSION 
In this study we tested the effect of itopride on some 
of the pathophysiological mechanisms attributed to 
the causation of symptoms in FD patients. Impaired 
accommodation is implied as one of the important 
factors considered to be associated with symptoms 
in FD patients. A primary objective of our study was 
to check whether itopride has any effect on gastric 
accommodation. We didn’t find any effect of itopride on 
gastric accommodation when assessed through gastric 
scintigraphy as compared to placebo. This finding is in 
disagreement with a similar study which showed that 
itopride worsens the gastric accommodation[29]. 
We also found that itopride didn’t effect gastric emp­
tying as assessed through 13C labeled octanoic acid 
breath test. A study done in Japan showed that itopride 
improves gastric emptying among dyspeptic patients[30]. 
On the other hand a cross over study that was also 
done in Japan showed that itopride does not improve 
gastric emptying[31]. Our study also found that itopride 
did not improve the drinking capacity as assessed 
through satiety drinking capacity test as compare to the 
placebo. This finding is in line with the similar findings in 
another study where it was found that itopride failed to 
improve the nutrient drink test induced symptoms[29]. 
Though in previous studies it was demonstrated 
  Symptoms Baseline End of four weeks 
Itopride Placebo P  value Itopride Placebo P  value
  Epigastric pain   3.0 (1.0)   4.0 (2.0) 0.18   2.0 (1.0)   2.0 (1.0) 0.83
  Epigastric discomfort   2.0 (1.0)   1.0 (1.0) 0.03   1.0 (1.0)   1.0 (1.0) 0.22
  Heart burn   1.0 (3.0)   1.0 (1.8) 0.37   1.0 (1.0)   1.0 (1.0) 0.74
  Upper abdominal pain   3.0 (2.0)   1.5 (2.5) 0.32   2.0 (1.0)   1.5 (1.0) 0.51
  Belching   1.0 (1.0)   1.0 (0.0) 0.10   1.0 (1.0)   1.0 (0.0) 0.02
  Nausea   2.0 (1.0)   1.0 (0.0) 0.04   1.0 (1.0)   1.0 (0.0) 0.08
  Early satiety   2.0 (2.0)   2.0 (3.0) 0.56   1.0 (1.0)   1.0 (0.0) 0.34
  Postprandial Fullness   2.0 (3.0)   2.0 (2.8) 0.82   1.0 (1.0)   1.0 (1.0) 0.25
  Total Symptom score 19.0 (9.0) 16.5 (5.0) 0.41 12.0 (3.0) 11.5 (4.5) 0.71
Table 3  Median Symptom score along with interquartile range at baseline and end of four weeks (placebo vs  itopride) n  = 31
80.00
60.00
40.00
20.00
0.00
-20.00
-3.00
-4.00
-5.00
-6.00
-7.00
-8.00
-9.00
Itopride                           Placebo Itopride                           Placebo
InterventionIntervention
95
%
CI
 c
ha
ng
e 
in
 s
ym
pt
om
 s
co
re
 (
en
dl
in
e 
- 
ba
se
lin
e)
95
%
CI
 c
ha
ng
e 
in
 d
rin
kn
g 
ca
pa
ci
ty
 (
en
dl
in
e 
- 
ba
se
lin
e)
P  = 0.74
P  = 0.51
Figure 3  Drinking capacity. Figure 4  Change in Symptom score by intervention group.
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